FDA Novel Drug Approvals – April 2023

May 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Qalsody tofersen 4/25/2023 To treat amyotrophic lateral sclerosis in

FDA Novel Drug Approvals – April 2024

May 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Xolremdi mavorixafor 4/26/2024 To treat WHIM syndrome (warts, hypogammaglobulinemia,

FDA Novel Drug Approvals – March 2024

Apr 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Voydeya danicopan 3/29/2024 To treat extravascular hemolysis with paroxysmal nocturnal

FDA Novel Drug Approvals – February 2024

Mar 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Letybo letibotulinumtoxinA-wlbg 2/29/2024 To temporarily improve the appearance of

FDA Novel Drug Approvals – January 2024

Feb 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Zelsuvmi berdazimer 1/5/2024 To treat molluscum contagiosum Drug Trials

FDA Novel Drug Approvals – December 2023

Jan 022024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Wainua eplontersen 12/21/2023 To treat polyneuropathy of hereditary transthyretin-mediated

FDA Novel Drug Approvals – November 2023

Dec 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Ogsiveo nirogacestat 11/27/2023 To treat adults with progressing desmoid

FDA Novel Drug Approvals – October 2023

Nov 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Loqtorzi toripalimab-tpzi 10/27/2023 To treat recurrent or metastatic nasopharyngeal

FDA Novel Drug Approvals – September 2023

Oct 022023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Rivfloza nedosiran 9/29/2023 To lower urinary oxalate levels in

FDA Novel Drug Approvals – August 2023

Sep 012023
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Veopoz pozelimab-bbfg 8/18/2023 To treat patients 1 year old

 Older Entries  Newer Entries